Collectively, the in vivo data using trametinib/dabrafenib resistant MEL28 cells argues that the combination of pazopanib with AR42, or with sodium valproate, should be explored as a new phase I/II trial in mutant B-RAF melanoma patients. The gene discussed is BRAF; the disease is melanoma.